Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 26:14:265-279.
doi: 10.2147/CEOR.S343249. eCollection 2022.

Budget Impact Analysis of Mepolizumab for Eligible Patients in the Setting of a Severe Asthma Clinic Within Dubai Health Authority (DHA)

Bassam Mahboub  1 , Ahmed Mohy  2 , Islam El-Amir  2 , Tamara Lukić  3 , Raef Gouhar  4 , Saeed Noibi  5
Affiliations

Budget Impact Analysis of Mepolizumab for Eligible Patients in the Setting of a Severe Asthma Clinic Within Dubai Health Authority (DHA)

Bassam Mahboub et al. Clinicoecon Outcomes Res. .

Abstract

Purpose: To estimate 5-years budgetary impact of introducing mepolizumab to eligible patients with uncontrolled severe eosinophilic asthma treated at a tertiary care hospital within Dubai Health Authority (DHA).

Patients and methods: A budget impact analysis (BIA) model was adapted to the setting of Rashid Hospital, DHA to estimate the budgetary implications of introducing first-in-class anti-IL5 (mepolizumab) as add-on therapy for eligible patients with severe eosinophilic asthma. The eligible patient population (n=60) was estimated from aggregate data provided by the clinic. Patients were eligible to treatment with mepolizumab if they had ≥2 exacerbation in the previous year and eosinophil count ≥150 cell/µL. The analysis compared the cost of treating patients in two alternative scenarios; a scenario where patients are treated with optimized usual care or with available biologic as add-on therapy, and a second scenario where mepolizumab is fully accessible to eligible patients.

Results: Administration of mepolizumab to eligible patients at Rashid Hospital is predicted to result in overall savings estimated at £270,545 over a 5-year time horizon. Exacerbation rates could not be indirectly compared for mepolizumab and omalizumab, since treatment continuation rules were defined differently. Therefore, these parameters were directly taken from the clinical trials for mepolizumab and omalizumab. The savings were estimated due to drug acquisition costs (£269,900) and estimated reduction in exacerbation (n=15). One-way sensitivity analysis showed that the model results was most sensitive to changing the method of calculating omalizumab dose and varying the drug acquisition cost of omalizumab by ±20%.

Conclusion: The BIA showed that full accessibility of mepolizumab to eligible severe asthma patients is predicted to be budget saving in the Dubai Health Authority. This evaluation is relevant to healthcare decision making as it demonstrates that mepolizumab is budget saving for eligible patients, while reducing burden by improving their control and symptoms.

Keywords: anti-IL5; asthma phenotypes; eosinophil count; exacerbations; treatment cost.

PubMed Disclaimer

Conflict of interest statement

BM has no potential or competing conflicts of interest, AM, IEA, TL, RG & SN are full-time employees of GSK, SN is also shareholder in GSK. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Model overview See attached figure to the manuscript.
See this image and copyright information in PMC

References

    1. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi: 10.1183/09031936.00202013 - DOI - PubMed
    1. Louis R. Severe asthma: how can we differentiate phenotypes? Swiss Med Wkly. 2009;139(19–20):247–277. - PubMed
    1. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716. doi: 10.1038/nm.2678 - DOI - PubMed
    1. Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–233. doi: 10.1007/s12016-018-8712-1 - DOI - PMC - PubMed
    1. Pavlidis STakahashi K, Kwong FN, et al. “T2-high” in severe asthma related to blood eosinophilexhaled nitric oxide and serum periostin. Eur Respir J. 2019;3553(1). - PubMed